SUN VALLEY, CA--(Marketwire - December 09, 2009) -
| Highlighted Links |
|
XTend Medical, (PINKSHEETS: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, today announced the company has completed and signed the asset purchase agreement with BioHarp, Korea.
The company released the following statement, “Mr. Lee, Mr. Friedman, and I are pleased to announce the completion of the asset purchase agreement between XTend Medical and BioHarp, Korea. The process took a little longer than anticipated but we’re extremely excited to finalize this agreement and work together with Mr. Lee to begin the manufacturing, marketing, and sales of the BioHarp device. XTend Medical has an incredible asset that will insure the company’s valuation moving forward. The device will, in our opinion, be known very soon as the premier medical diagnostic tool worldwide. We’re thoroughly impressed with the team behind the BioHarp and are looking forward to a long lasting relationship. XTend Medical will move quickly to gain sales in Korea, China, Japan, and other countries that have expressed interest in the unit and to have a combined operation so our reach is global in nature. We anticipate the sales of the BioHarp to reach phenomenal numbers in the coming years,” stated Mr. Paul D. Lisenby, CEO of XTend Medical.
Mr. Lee, CEO of BioHarp, Korea, added, “I am extremely excited about the future of the BioHarp. Our team, combined with the management of XTend Medical, will insure the company’s success. We look forward to working closely with Mr. Lisenby and Mr. Friedman as we begin the manufacturing and sales process globally and deploy the BioHarp to health organizations throughout the world.”
About XTend Medical
XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis. For further information, please contact them at info@bioharpunius.com
The new website can be located at www.bioharpunius.com
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.
CONTACT
info@bioharpunius.com
